Precision 2: an open explorative phase II, open label study of afatinib in the treatment of advanced cancer carrying an EGFR, a HER2 or a HER3 mutation. - Precision 2

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2016
This article has no abstract
Epistemonikos ID: 789dbc849fafe93fc909a4a62927ca0d47165c9a
First added on: Apr 17, 2025